Enliven Therapeutics
ELVN
ELVN
93 hedge funds and large institutions have $1.13B invested in Enliven Therapeutics in 2024 Q2 according to their latest regulatory filings, with 32 funds opening new positions, 37 increasing their positions, 14 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
26% more funds holding
Funds holding: 74 → 93 (+19)
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
4.79% less ownership
Funds ownership: 107.51% → 102.72% (-4.8%)
Holders
93
Holding in Top 10
7
Calls
$287K
Puts
$14K
Top Buyers
| 1 | +$21.4M | |
| 2 | +$19.6M | |
| 3 | +$18.2M | |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$18M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$15.2M |
Top Sellers
| 1 | -$28.6M | |
| 2 | -$24.3M | |
| 3 | -$22.9M | |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$1.09M |